301. FAT1 Expression and Mutation Status In Adult Acute Lymphoblastic Leukemia
- Author
-
Cornelia Schlee, Eva Kristin von der Heide, Helmut Blum, Claudia D. Baldus, Nicola Gökbuget, Marco Seehawer, Stefan Schwartz, Martin Neumann, Alexander Graf, Stefan Krebs, Dieter Hoelzer, Sandra Heesch, Philipp A. Greif, and Sebastian Vosberg
- Subjects
Immunology ,CD34 ,Wnt signaling pathway ,Cell Biology ,Hematology ,Biology ,medicine.disease ,Bioinformatics ,Biochemistry ,Haematopoiesis ,medicine.anatomical_structure ,Immunophenotyping ,Adult Acute Lymphoblastic Leukemia ,medicine ,Cancer research ,Bone marrow ,Burkitt's lymphoma ,FAT1 - Abstract
Introduction FAT1 belongs to the FAT protocadherin family, a drosophila homologous gene involved in development processes. Recently, FAT1 gained large interest as it is mutated in various cancers. Besides the known function of cell-cell interaction and polarity, FAT1 loss of function mutations have been linked to dysregulation of the WNT pathway in solid tumors. In acute lymphoblastic leukemia (ALL), aberrantly high expression of FAT1 was claimed to be associated with inferior outcome in pediatric B-lineage ALL. Herein, we investigated the yet unknown frequency and relevance of FAT1 expression and mutation in a large, homogenously treated cohort of adult ALL patients. Patients and Methods We investigated FAT1 expression in diagnostic bone marrow (BM) samples of 112 T-ALL, 122 B-lineage ALL, and additional 63 early T-cell precursor (ETP) ALL patients by real time (RT)-PCR. Patients were enrolled in trials of the German Multicenter Study Group for Adult ALL (GMALL) and outcome was investigated for patients into GMALL trials 06/99 and 07/03. Using the T-cell line BE13 as reference, we defined patients with FAT1 expression higher than BE13 as FAT1pos (0.01-38.5) and patients with a lower expression as FAT1neg ( Results Normal hematopoietic cells including unselected BM cells, CD34+-progenitors, or CD3+ T-cells from healthy donors lacked FAT1 expression (30.000/µL at diagnosis compared to FAT1neg T-ALL patients (78% vs. 42%, p Conclusion This first comprehensive analysis on FAT1 in a large cohort of adult patients with ALL shows a high frequency of FAT1 expression. Higher FAT1 expression occurred in ALL patients with more mature immunophenotype linking FAT1 to cell-cell adhesion and polarity, thymic homing and interaction with the BM niche. This yet unreported high mutation rate of 12 % in adult T-ALL makes FAT1 to one of the most frequently mutated genes in T-ALL. The link of inactivating FAT1 mutations to aberrant activation of the WNT pathway, as reported in solid tumors, might allow the development of refined treatment options. In summary, these data make FAT1 a promising candidate for disease monitoring, risk stratification and development of targeted therapies. Disclosures: Krebs: Illumina: Honoraria. Greif:Illumina: Honoraria.
- Published
- 2013
- Full Text
- View/download PDF